Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients.
possibly paving the way for new therapies that can either hone the pathway's cancer-killing role or reduce its role in inflammation.
With the new insights, we can better identify the good stem cells and use them more efficiently and safely in clinical therapies.
With the growing importance of stem cell therapy, this study is a fitting example of how upstream research can potentially benefit
#Virus re-engineered to deliver therapies to cells Stanford researchers have ripped the guts out of a virus
and therapies directly where they are needed. The study reported today in the Proceedings of the National Academy of Sciences breathes new life into the field of targeted delivery,
Insights could lead to targeted therapies The research team performed a proof of principle experiment to demonstrate how valuable information about metastatic gene expression could be for drug development.
but more information about the microbiome is needed to effectively design such therapies.""The paper's lead author is Hiroki Ando, an MIT research scientist.
since the results may change the standard of care in patients with advanced kidney cancer who have received prior standard therapy that targets the vascular endothelial growth factor receptor (VEGFR)."
"Although treatment with VEGFR-targeted drugs has been very effective in the first line of therapy for patients with advanced kidney cancer,
Regaining tumour control after prior targeted therapy may reduce symptoms related to kidney cancer and eventually help patients live longer."
"An early evaluation of overall survival from the ongoing METEOR trial has shown a strong trend indicating that survival may be improved in patients receiving cabozantinib compared to standard therapy.
Their disease had to have progressed within six months of receiving prior treatment with VEGFR tyrosine kinase inhibitor (TKI) therapy.
or resistance to standard therapies is critical for improving long-term outcome for our patients with advanced kidney cancer.
Combinations with other emerging therapies, such as agents boosting the immune system, are of interest and an early stage clinical trial combining cabozantinib with immune checkpoint inhibitors has been initiated in urological cancers,
In the USA, the Food and Drug Administration (FDA) has designated it as a breakthrough therapy,
But in order to undertake a complete therapy, we need neuronal tissue that links all RPE cells to the cones.
offering the possibility of directly testing potential avenues for therapy on the patient's own tissues s
and with the group Bacterial Infections and Antimicrobial Therapies led by Dr Eduard Torrents, of the Institute for Bioengineering of Catalonia (IBEC) I
With a poor prognosis and limited options for targeted therapies, fighting SS needs new treatment approaches.
These results highlight the genetic vulnerabilities that we can use in designing precision medicine therapies."
From this, they will also be able to identify distinct subsets of the disease to stratify patients for precision therapy based on their unique mutations and the inhibitors available for those mutations s
"The two therapies were tested together in laboratory experiments using human immune cells and in mice that were engineered to have a human immune system.
as any patient prescribed URMC-099 would also be taking antiretroviral therapy. The goal was to determine
"Our ultimate hope is that we're able to create a therapy that could be given much less frequently than the daily therapy that is required today,
This ideal therapy has remained in the realm of science fiction until now.''The team stresses that there are significant hurdles before this could offer new treatments--a key issue is being able to alter the heart to be light-sensitised
will pave the way for the development of restorative therapies for thousands of patients. Dr Davinia Fernández-Espejo
""However, before we take the crucial step of developing targeted therapies to help these patients,
Dr Fernández-Espejo added,"The ultimate aim is to use this information in targeted therapies that can drastically improve the quality of life of patients.
"Though it may be a number of years before an effective therapy is developed, the team believe that a significant milestone has been reached with the discovery e
and design of therapies to treat them. But finding a specific biomarker in a massive amount of genetic code is hard.
because the therapy has been shown to delay and even reverse disease progression of Parkinson's disease in preclinical models.
"it will be several years before a potential glioblastoma therapy can be tested in humans. SKOG102 must first undergo detailed pharmacodynamic,
Such sensors could also be used to monitor the effectiveness of stem cell therapies Jasanoff says."
"As stem cell therapies are developed, it's going to be necessary to have noninvasive tools that enable you to measure them,
From the researchers'point of view, this goes some way into explaining why some people are resistant to some forms of cancer therapy.
Arrayso, does the absence of the VRAC protein promote therapy resistances?""The data suggest that LRRC8A
Heparin is used widely as an anticoagulant in cardiovascular surgery as well as in postoperative and long-term therapy.
it may be worth developing therapies based on it even if it is not fully understoods long as it can be proved to be safe and effective t
While medical therapy is usually the first line of treatment, a new minimally invasive implant can dramatically reduce symptoms for men. his is a safe procedure for men with BPH to improve urination
the researchers were able to durably wipe out cancer cells in mice implanted with cells from the drug-resistant tumor. ven in cancers that are responding to targeted therapy by conventional criteria,
n this work we have begun to crack open the question of why residual disease persists after targeted therapy.
suggesting that combining a compound like PBS-1086 with erlotinib at the outset of therapy may help to prevent acquired drug resistance in EGFR-mutant NSCLC.
Combined drug regimens designed to overcome drug resistance at the outset of therapy are now the norm in treating certain forms of melanoma,
and that a substantial number of patients, this could be a very powerful companion therapy to minimize
new therapies may be ahead Duke researchers have developed a new method to precisely control when genes are turned on and active.
and how it relates to disease or response to drug therapies. Gersbach added, ot only can you start to answer those questions,
#In first human study, new antibody therapy shows promise in suppressing HIV infection In the first results to emerge from HIV patient trials of a new generation of so-called broadly neutralizing antibodies,
Rockefeller University researchers have found the experimental therapy can dramatically reduce the amount of virus present in a patient blood.
an antibody therapy for HIV might require treatment just once every few months, compared to daily regimens of antiretroviral drugs that are now the front-line treatment for HIV. n contrast to conventional antiretroviral therapy,
antibody-mediated therapy can also engage the patient immune cells, which can help to better neutralize the virus,
says co-first author Florian Klein, also assistant professor of clinical investigation in the Nussenzweig laboratory.
#New Way to Fight Cancer Targeted cancer therapies work by blocking a single oncogenic pathway to halt tumor growth.
they are often able to evade these therapies and regrow. Moreover, tumors contain a small portion of cancer stem cells that are believed to be responsible for tumor initiation, metastasis and drug resistance.
a treatment for APL that is considered to be the first example of modern targeted cancer therapy,
and are part of the body first-line of defensehe so-called nnateimmune systemt first work in concert with the therapy
and first author Lee B. Rivera, Phd, a UCSF postdoctoral scholar in the Bergers laboratory, also identified a potential way to stop myeloid cells from sabotaging the therapy
During anti-angiogenic therapy, said Bergers, the Neill H. and Linda S. Brownstein Endowed Chair in Brain tumor Research and a member of the UCSF Helen Diller Family Comprehensive Cancer Center,
But we have learned that we can also manipulate this process to make therapy more effective.
The researchers found that during the initial phase of therapy, VEGF inhibition stimulates myeloid cells within the tumor to release the signaling protein CXCL14,
During this phase, myeloid cells complement the therapy to prevent the creation of new blood vessels,
therapy becomes ineffective, and you have said relapse, she. In breast cancer, Bergers noted, anti-VEGF therapy is not very effective to begin with. his tells us why,
she said. n a laboratory model of breast cancer, about 45 percent of myeloid cells are activated already,
so the cancer just ignores the therapy. The researchers found that targeting specific innate immune cells within the tumor did not reverse the negative effects of PI3K activation.
This so-called myeloid-cell oscillation maintained the tumor resistance to the therapy. Instead, said Bergers,
Ultimately, the researchers demonstrated that combining a PI3K inhibitor with anti-VEGF therapy prevented relapse
Bergers noted that the discovery potentially gives physicians a way to determine how effective anti-VEGF therapy might be in individual patients
as well as to monitor the course of therapy. n some new patients, we could test to determine how many myeloid cells in the tumor were activated already,
which could tell us to what extent the tumor would still be responsive to anti-VEGF therapy,
In patients undergoing therapy, e could take advantage of the fact that myeloid cells occur not only in the tumor,
Right now, one of the major issues in anti-VEGF therapy is that there are no biomarkers for response and relapse. t
we can be more precise in defining the therapy moving forward. Eye on immune therapies and prevention In his lab, professor of immunology Dr. Kevan Herold has used the technology to explore key questions about type 1 diabetes, an autoimmune condition.
Cytof is helping his team get more data about a limited repertoire of cells specific to type 1 diabetes
are involved there pathways that we can target for therapies? Those are the types of questions wee interested in.
The goal is not only to develop immune therapy to treat type 1 diabetes but potentially to use the data for prevention. here are antigen-reactive T cells that are found in individuals at risk for type 1 diabetes,
and the immune therapies that emerge. e tend to think of our analyses of cells as unidimensional or bi-dimensional.
A New Direction for Drug Research The startling discovery of TMPRSS2 role in triggering cancer pain may lead to the creation of targeted cancer pain therapies that effectively shut down the expression of this gene
This could eventually become an effective therapy for the lungs of patients, regardless of the mutation type.
and that treatment of human disorders with nanowrapped therapies is years away a
#Small tilt in magnets makes them viable memory chips UC Berkeley researchers have discovered a new way to switch the polarization of nanomagnets,
#Real-time data for cancer therapy In the battle against cancer, which kills nearly 8 million people worldwide each year,
however, is good reconnaissance a reliable way to obtain real-time data about how well a particular therapy is working for any given patient.
and adjust dosages or switch therapies accordingly. Making cancer treatments more targeted and precise would boost their efficacy
and adjust or switch therapies. Photo courtesy of the researchers. Measurements without MRI The sensors developed by Cima team provide real-time,
In fact, some therapies will trigger an immune system reaction, and the inflammation will make the tumor appear to be growing,
even while the therapy is effective. Oxygen levels, meanwhile, can help doctors gauge the proper dose of a therapy such as radiation,
since tumors thrive in low-oxygen (hypoxic) conditions. t turns out that the more hypoxic the tumor is,
leading to potentially better therapies and easier tumor identification. The findings have been licensed to Genomeon, a company co-founded by Garner to develop new ways to assess cancer risk,
the optoclamp could facilitate research into new therapies for epilepsy, Parkinson disease, chronic pain and even depression. ur work establishes a versatile test bed for creating the responsive neurotherapeutic tools of the future,
said Steve Potter, an associate professor in the Wallace H. Coulter Department of Biomedical engineering at Georgia Tech and Emory University. eural modulation therapies of the future,
said Newman. his is potentially a very big deal in terms of developing therapies for aberrant forms of synaptic plasticity.
such as the bionic eye or retinal stem cell therapy. c
#DNA-Guided 3-D Printing of Human Tissue Is unveiled A UCSF-led team has developed a technique to build tiny models of human tissues, called organoids,
and could have implications that go far beyond basic neuroscience from informing education policy to developing new therapies for neurological disorders such as epilepsy.
when we age, has enormous implications that go beyond fundamental neuroscience, from informing education policies to developing new therapies for neurological disorders such as epilepsy
#Filling a void in stem cell therapy Stem cell therapies are limited often by low survival of transplanted stem cells
Stem cell therapies bear tremendous hopes for the repair of many tissues and bone or even the replacement of entire organs.
and function correctly at the site of injury to be useful for clinical regenerative therapies.
More Precise Cancer Therapies UCSFUC San francisco researchers have engineered a molecular n switchthat allows tight control over the actions of T cells,
immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe,
scientists pursuing cell therapy, one branch of the burgeoning field of cancer immunotherapy, have been refining cell-surface sensors known as chimeric antigen receptors, or CARS.
Dangers of CAR T cell Therapy CAR-equipped T cells have proven to be remarkably successful in the treatment of various forms of chemotherapy-resistant leukemia
But CAR T cell therapy can cause side effects so serious that they may require monitoring in an Intensive care unit several patients have died after receiving CAR T cells
These combined control capabilities could be employed to manage the various side effects of CAR T therapy.
and the ability to document these alterations aid in the development of novel therapies. ethylation is really key in development,
and in efforts toward an effective therapy. But the implications are even broader because the approaches that the investigators used could aid therapy development for a vast array of other mitochondrial diseases,
said Maryann Redford, D d. S m. P. H.,a program director in Collaborative Clinical Research at NIH National Eye Institute,
and testing potential therapies for such diseases. Until now here was no efficient way to get DNA into mitochondria,
But in order to undertake a complete therapy, we need neuronal tissue that links all RPE cells to the cones.
offering the possibility of directly testing potential avenues for therapy on the patient own tissues e
This ideal therapy has remained in the realm of science fiction until now. The team stresses that there are significant hurdles before this could offer new treatments a key issue is being able to alter the heart to be light-sensitised
and design of therapies to treat them. But finding a specific biomarker in a massive amount of genetic code is hard.
This ideal therapy has remained in the realm of science fiction until now. he team stresses that there are significant hurdles before this could offer new treatments a key issue is being able to alter the heart to be light-sensitised
and therapies that might work in humans. The researchers found that genetically matched kidney organoids without disease-linked mutations showed no signs of either disease.
better ways of testing out drugs and therapies that might work in humans. g
#Snake venom helps hydrogels stop the bleeding Rice university lab employs clotting powers of viper-derived drug,
It has been used in various therapies as a way to remove excess fibrin proteins from the blood to treat thrombosis and as a topical hemostat.
#Scientists create a new simple method to create stem cells Many new innovative therapies that scientists come up with rely on stem cells,
especially when immune therapy and regenerative medicine are considered. However, these promising research fields are limited by the difficulty of creating stem cells.
which could then be used for regenerative medicine or immune therapy. It is hard to overestimate researches like that.
which in turn will most likely spawn many new researches and new therapies for harsh conditions in immune therapy and regenerative medicine.
and there are currently no targeted therapies available. ersonalised medicine is about targeting treatment to an individual particular genetic profile,
which means that any drug therapy will likely have few side effects. Second the location of the receptors on the outer surface of cancer cells means they can be accessed easily by drugs.
and other members of this specific class of receptors have been targeted successfully for cancer therapies. The cancer drugs Herceptin, Gleevec and Iressa all target receptors of this class.
#Nanotechnology could spur new heart treatment for arrthymia A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia,
The major challenge of adapting the therapy to heart cells was developing a nanoparticle small enough to penetrate the tiny pores inside heart capillaries,
and a research lab specialist in internal medicine. his cell-selective therapy may represent an innovative concept to overcome some of the current limitations of cardiac ablation,
so may find applications in drug toxicity tests, the search for new drugs and cell therapy.
The goal of some antiviral therapies, therefore, is to buy more and give the immune system a leg up on the virus. A new study led by Bruce Freedman
The work paves the way toward designing a potential broad-spectrum drug that could serve as a therapy for a number of serious viral infections. ur work is aimed at handicapping the virus
said Freedman. e could also imagine this type of drug would be part of a cocktail therapy,
In addition, if used as part of a combination therapy, ORAI inhibitors could be administered at lower doses m
but it also suggests that these physical channels might be exploitable to deliver drug therapies. hope that the tools we have developed,
or use them to deliver lifesaving therapies. o
#New treatment targets cancers with particular genetic signature Oxford university researchers have found the Achilles heel of certain cancer cells mutations in a gene called SETD2.
and provide a step towards personalized cancer therapy i
#Google Project Loon Set to Enmesh the Globe with Internet Balloons by 2016 Project Loon is yet another highly ambitious project of the tech-giant Google,
Spritam (levetiracetam) is an oral adjunctive therapy to treat a range of seizures in adults and children with epilepsy.
According to Aprecia, potential therapies made via Zipdose are assembled in layers without using compression forces or traditional moulding techniques.
n conjunction with medication and current psychological therapies, Wizard could help people with schizophrenia minimise the impact of their illness on everyday life. eople with schizophrenia often find studying
#Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied Ninety percent of children
or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy CTL019 developed at the Perelman School of medicine at the University of Pennsylvania.
The durable responses we have observed with CTL019 therapy are unprecedented. Shannon Maude MD Phd an assistant professor of Pediatrics and a pediatric oncologist at CHOP and Noelle Frey MD MSCE an assistant professor of Medicine and an oncologist at Penn's Abramson's Cancer Center
Nineteen patients in the study remain in remission 15 with this therapy alone including a 9 year old who was the first ALL patient to receive the therapy more than two years ago.
Five patients went off-study for alternate therapy three of whom proceeded to allogeneic stem cell transplants while in remission.
Our results support that CTL019 can produce long-lasting remissions for certain heavily pre-treated ALL patients without further therapy Frey said.
In July 2014 the U s. Food and Drug Administration granted CTL019 its Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric ALL a step
and review of new medicines that treat serious or life-threatening conditions if a therapy has demonstrated substantial advantages over available treatments.
CTL019 is personalized the first cellular therapy to receive the designation. The first multicenter CTL019 trial has opened recently in the U s
and cells offer new solutions for cancer diagnosis and therapy. Understanding the interdependency of physiochemical properties of nanomedicines in correlation to their biological responses
Mcdonnell and colleagues searched libraries of thousands of approved therapies to identify those that rely on copper to achieve their results.
or similar compounds and copper especially beneficial for men who have been on hormone therapies that have failed to slow tumor growth.
Unfortunately hormone therapies do not cure prostate cancer and most patients experience relapse of their disease to a hormone-refractory
Mcdonnell said clinical trials of the combination therapy are planned in upcoming months. Andrew Armstrong M d. associate professor of medicine was involved with a recent study at Duke testing disulfiram in men with advanced prostate cancer.
No efficient causal therapy exists for HCC patients of which approximately 800000 die every year. T cells involved in the development of fatty liver disease NASH
Researchers used the new therapy to inhibit a pathway in the cancer cells known as mtor signaling--putting the brakes on this pathway combined with the current standard therapy caused more of the cancer cells to die.
and therapies that can be tested in the clinic provides the greatest hope for brain cancer patients
understanding of diseases and possibly to new therapies according to UC San francisco scientists. The key to the advance is a new invention called the Suntag a series of molecular hooks for hanging multiple copies of biologically active molecules onto a single protein scaffold used to target genes or other molecules.
but such compounds have not been developed successfully as therapies because they also block the many important processes controlled by NF-kb in healthy cells causing serious toxic side effects.
so drugs targeting STAT3 could be used in cancer therapy. However STAT3 is also important in the development of the immune system.
Anti-STAT3 therapy may thus be highly promising. The so-called Signal Transducers and Activators of Transcription or STATS are key components of many different signalling pathways.
Considerable efforts are going into developing inhibitors of STAT3 for use in cancer therapy but it is unclear
senior author of the new study with TSRI Assistant professor of Chemistry Luke Leman. his research clears a big step toward clinical implementation of new therapies.
With the option of an orally effective peptide, Ghadiri believes researchers are closer to developing an accessible new therapy for atherosclerosis.
The researchers believe that finding new targets in the gastrointestinal tract could lead to new therapies for many more diseases. hat one of the fun things in scienceow we get to follow up on these different avenues,
and opened the door for drug discovery and transplantation therapy in diabetes, "Fuchs said. And Jose Oberholtzer, M d.,Associate professor of Surgery, Endocrinology and Diabetes,
In particular, this advance opens to doors to an essentially limitless supply of tissue for diabetic patients awaiting cell therapy."
and may provide a resource for discovery of beta cell therapies that promote survival or regeneration of beta cells and development of screening biomarkers to monitor beta cell health and survival to guide therapeutic
which conservative therapy or surveillance would be appropriate treatment, the clinical challenge is not only how to identify those with prostate cancer,
We are working now to improve the technology to achieve the imaging precision we need to make broadly effective therapies,
#Worlds first novel method for label-free identification of stem cells will lead to more consistent, efficacious stem cell therapies,
Dry powder inhaler formulation Despite advances in vaccination and antimicrobial therapy, community-acquired pneumonia remains a leading cause of morbidity and mortality, even in highly developed countries.
Current experimental drugs generally target only one of Ebola's five species."The current growing epidemic demonstrates the need for effective broad-range Ebola virus therapies,
or new Ebola species. Development of a broadly acting therapy is an important long-term goal that would allow cost-effective stockpiling of a universal Ebola treatment."
and more efficient targeted therapy to improve the clinical outcome. Story Source: The above story is provided based on materials by University of Kansas. Note:
and may be key to developing new drugs and therapies. Specifically principal investigator Albert R. La Spada MD Phd professor of cellular and molecular medicine chief of the Division of Genetics in the Department of Pediatrics and associate director of the Institute for Genomic
and disease and finding personalized therapies Maggert said. However this topic is incomplete unless biologists can look at the entire genome.
The optimal drug therapies we have today often aren't enough to manage this disease for some patients
so we are always looking for new types of therapies. Abraham and other cardiovascular researchers at seven U s. centers examined an extra-aortic counterpulsation system called C-Pulse made by Sunshine Heart Inc. It's a cuff that wraps around the aorta
Drug and device therapies that are currently available for heart failure improve that same quality of life score by only five or 10 points.
and antibiotic therapy could reduce that risk in future studies. There were no hospitalizations among the participants for stroke thrombosis sepsis or bleeding
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011